{"slug":"wave5-sponsor","tag":"wave5-sponsor","variants":["wave5-sponsor"],"description":"No description yet","count":8,"kinds":{"company":8},"related":[],"records":[{"id":"criterium","kind":"company","name":"Criterium","route":"/companies/criterium/","tldr":"Criterium is a US company in Saratoga Springs, New York, that is the lead sponsor of four cancer trials in OnCo, all testing other makers' drugs: fruquintinib with TAS-102 in colorectal cancer and tucatinib, alpelisib or palbociclib combinations in breast cancer."},{"id":"artios-pharma","kind":"company","name":"Artios Pharma","route":"/companies/artios-pharma/","tldr":"Artios Pharma is a Cambridge, UK biotechnology company that leads two cancer trials in OnCo, testing its DNA damage response inhibitors ART0380 (ATR) and ART6043 (DNA polymerase theta) in advanced solid tumours."},{"id":"ambrx","kind":"company","name":"Ambrx","route":"/companies/ambrx/","tldr":"Ambrx is a La Jolla, California biotechnology company founded in 2003 whose HER2 antibody-drug conjugate ARX788 is in OnCo's phase 3 ACE-Breast-02 trial (with Zhejiang Medicine, in China) and the global phase 2 ACE-Breast-03 trial after trastuzumab deruxtecan."},{"id":"nerviano-medical-sciences","kind":"company","name":"Nerviano Medical Sciences","route":"/companies/nerviano-medical-sciences/","tldr":"Nerviano Medical Sciences is an Italian drug-discovery company founded in 2004 in Nerviano, near Milan, that leads two cancer trials in OnCo: the PARP1-selective inhibitor atamparib in advanced solid tumours and NMS-03305293 with temozolomide in recurrent glioblastoma."},{"id":"qurient","kind":"company","name":"Qurient","route":"/companies/qurient/","tldr":"Qurient is a South Korean biotechnology company in Seongnam that leads two cancer trials in OnCo, testing the selective CDK7 inhibitor Q901 and the Axl/Mer/CSF1R inhibitor Q702, each with pembrolizumab, in advanced solid tumours."},{"id":"immunovaccine","kind":"company","name":"Immunovaccine (IMV)","route":"/companies/immunovaccine/","tldr":"Immunovaccine (IMV) is a Canadian biotechnology company founded in 2000 in Halifax, Nova Scotia, whose survivin-targeted immunotherapy DPX-Survivac is tested with pembrolizumab and low-dose cyclophosphamide in two OnCo trials, in relapsed diffuse large B-cell lymphoma and in selected solid tumours."},{"id":"gruenenthal","kind":"company","name":"Grünenthal","route":"/companies/gruenenthal/","tldr":"Grünenthal is a German pharmaceutical company founded in 1946 in Aachen. In OnCo it is the marketing authorisation holder of PecFent, a fentanyl nasal spray authorised in the EU for breakthrough pain in adults on maintenance opioids for chronic cancer pain."},{"id":"4sc","kind":"company","name":"4SC","route":"/companies/4sc/","tldr":"4SC is a listed German biotechnology company founded in 1997 in Planegg-Martinsried, near Munich. It applied to the EMA for its HDAC inhibitor resminostat (Kinselby) in advanced mycosis fungoides and Sézary syndrome and received a negative opinion in May 2025."}]}